The disruption of alcohol use (AUD) is a devastating disease determined by a period of drinking and severe withdrawals, often causing chronic relapse courses. Initially, alcohol was consumed for the effects of positive reinforcement, but the stages of AUD were then marked by drinking to reduce the negative emotional state induced withdrawal. The brain stress response system in Extended Amygdala is recruited with excessive alcohol intake, sensitive with recurring withdrawals, and contributes to addiction development.
In this study, we investigated one of the brain stress response systems, polypeptides of the pituitary clasp (Pacip), and the receptor of Serumpun, PAC1R, in the behavior induced by alcohol. During acute withdrawal, mice exposed to chronic intermittent ethanol steam (ethanol dependent) display a significant increase in the level of PACP in the nucleus bed of the terminal stria (BNST), the brain area in repetition of Amygdala involved critically in stress and withdrawal.
There were no changes to the Level of Pacap observed at the central core of Amygdala. The specific microinfusion of the site of PAC1R PACAP antagonists (6-38) into the dose of BNST-Department blocks excessive alcohol intake in mice that depend on ethanol without affecting overall water intake or basal ethanol intake in control, nondependent mice. Intra-BNST PACAP (6-38) also reverses behavior such as anxiety caused by ethanol in mice that depend on ethanol, but does not affect this size in mouse control. Our findings show that chronic chronic ethanol exposure recruits the PACAP / PAC1R system from BNST and that this neuroaptasi mediates alcohol drinking behavior and such anxiety observed during withdrawal, indicating that this system represents the main brain stress element responsible for the negative reinforcement associated with ” The dark side is “alcoholism.
The modified circadian activity and rhythmic rhythm / wake in a stable tube only polypeptide (stop) null mouse schizophrenia model
Sleep disorders and circadian rhythm generally occur in individuals with schizophrenia. The stable tubules are only polypeptides (ko) showing damage to behavior resembling symptoms of schizophrenia. We previously reported that stopping the mouse to bed slept less and had a more fragmented sleep and woke up rather than a wild type Litter friend under the light / dark cycle (LD) (Proft et al., Schizoph Bull. 2016; 42 (5): 1207-1215 ): 1207-1215). Here, we assess the phenotype of male circadian stops KO mice by examining the rhythm of the activity operating wheel and the purpose of sleep / wake EEG / EGS which is defined under the conditions of LD and Darkness (DD). The rhythm of activity operates wheels in KO and wild type mice is also heard in LD, and has a similar running period in DD. The shift in postponing phase in response to light pulses given at the beginning of the active phase below DD is preserved in KO mice.
KO mice have far lower activity levels, lower amplitude activity rhythms, less stable activities, and more fragmented activities than wild type mice in both lighting conditions. Ko Mice also spends more time and less time in the movement of fast eye movement (REMS) and non-REMS (NREMS) in LD and DD conditions, with a decrease in NREMS concentrated in the active phase. KO MICE also shows a changeful EEG feature and a higher rhythm of amplitude in Wake and Nrem (but not brakes) in both lighting conditions, with longer running periods in DD, compared to wild type mice. These results indicate that zero mutations stop in mice change the rules of sleep physiology / wake up expression of activity rhythms, but not roughly interfere with circadian mechanisms.
Pregnancy is inadequate by severely hypercholaneemia refractories from sodium taurocholate co-transportation of polypeptide deficiency
Sodium Taurochole transports polypeptide deficiency is the condition of a rare metabolic autosomic recessive condition which results in plasma bile acid levels that increase critically. Hypercholanaemia in similar conditions such as intrahepatic pregnancy cholestasis has been associated with an increased risk of midwifery results including birth birth.
We present the first case of the Sodium Taurocholate polypeptide deficiency in the current pregnancy in patients with one previously dead birth in the context of severe hypercolanaemia, where conventional care for cholestasis including urshodoxicolic acid, rifampicin and cholestyramine is not effective. Terapeutic plasma exchanges and new treatment with elobixibly tried with diverse results. Pregnancy produces premature premature delivery of a baby living at a gestation of 32 weeks.

Hydrophilic interactions dominate reverse temperature dependence on polypeptide hydration-free energy associated with hydrophobicity
We overcome the association of hydrophobic driving forces in folding protein with reverse temperature dependence on protein hydration, where stabilizing the effects of hydration strengthens with increasing physiological temperatures in the physiological range. Calculation of all atoms from free energy free energy conformer deca-alanine, holistically including backbone interaction and side chains together, indicating that interesting peptidide solvent interactions and thermal expansion solvents dominate the upside signature temperature that has been interpreted traditionally as hydrophobic stabilization Protein in aqueous solution.
IRF7 Peptide |
3941P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) IRF7 peptide |
IRF7 Peptide |
3943P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) IRF7 peptide |
IRF8 Peptide |
3401P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) IRF8 peptide |
IRF5 Peptide |
45-075P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (CT) IRF5 Peptide |
IRF7 Peptide |
8991P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) a TRAF-interacting protein |
IRF3 Peptide |
3397P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) IRF3 peptide |
IRF3 Peptide |
3399P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) IRF3 peptide |
IRF2 Peptide |
45-780P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: IRF2 Peptide |
IRF6 Peptide |
45-781P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: IRF6 Peptide |
IRF2BP1 Peptide |
42-415P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) IRF2BP1 Peptide |
IRF2BP2 Peptide |
42-416P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) IRF2BP2 Peptide |
IRF2BP1 Peptide |
42-441P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) IRF2BP1 Peptide |
IRF2BP2 Peptide |
6705P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (CT) IRF2BP2 peptide |
IRF2BP2 Peptide |
5601P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (NT) IRF2BP2 peptide |
IRF3 Blocking Peptide |
AF6438-BP |
Affbiotech |
1mg |
EUR 234 |
IRF6 Blocking Peptide |
33R-2986 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of IRF6 antibody, catalog no. 70R-1620 |
IRF8 Blocking Peptide |
33R-7617 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of IRF8 antibody, catalog no. 70R-7861 |
IRF1 Blocking Peptide |
DF12645-BP |
Affbiotech |
1mg |
EUR 234 |
IRF7 Blocking Peptide |
DF7503-BP |
Affbiotech |
1mg |
EUR 234 |
IRF3 Blocking Peptide |
DF6895-BP |
Affbiotech |
1mg |
EUR 234 |
IRF9 Blocking Peptide |
DF8179-BP |
Affbiotech |
1mg |
EUR 234 |
IRF5 Blocking Peptide |
DF6283-BP |
Affbiotech |
1mg |
EUR 234 |
IRF2 Blocking Peptide |
DF3093-BP |
Affbiotech |
1mg |
EUR 234 |
IRF1 Blocking Peptide |
20-abx161139 |
Abbexa |
|
|
|
IRF5 Blocking Peptide |
20-abx161140 |
Abbexa |
|
|
|
IRF3 Blocking Peptide |
20-abx162126 |
Abbexa |
|
|
|
Irf2bp1 Blocking Peptide |
33R-1374 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of CRYM antibody, catalog no. 70R-3722 |
IRF2BP1 Blocking Peptide |
33R-5498 |
Fitzgerald |
100 ug |
EUR 216 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of IRF2BP1 antibody, catalog no. 70R-3119 |
IRF2BP2 Blocking Peptide |
DF13096-BP |
Affbiotech |
1mg |
EUR 234 |
IRF-3 Blocking Peptide |
AF7887-BP |
Affbiotech |
1mg |
EUR 234 |
phospho-IRF4(Tyr122/125) Blocking Peptide |
AF4476-BP |
Affbiotech |
1mg |
EUR 234 |
IRF3 (pS385) Blocking Peptide |
20-abx061746 |
Abbexa |
|
|
|
IRF4 siRNA |
20-abx920800 |
Abbexa |
|
|
|
IRF4 siRNA |
20-abx920801 |
Abbexa |
|
|
|
IRF4 Antibody |
25305-100ul |
SAB |
100ul |
EUR 468 |
IRF4 antibody |
38169-100ul |
SAB |
100ul |
EUR 302.4 |
IRF4 Antibody |
37663-100ul |
SAB |
100ul |
EUR 302.4 |
IRF4 Antibody |
43509-100ul |
SAB |
100ul |
EUR 302.4 |
IRF4 Antibody |
6307-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: IRF4 Antibody: Interferons (IFNs) are involved in a multitude of immune interactions during viral infections and play a major role in both the induction and regulation of innate and adaptive antiviral mechanisms. During infection, host-virus interactions signal downstream molecules such as transcription factors such as IFN regulatory factor-3 (IRF3) which can act to stimulate transcription of IFN-alpha/beta genes. Another member, IRF7 has been shown to play a role in the transcriptional activation of virus-inducible cellular genes, including interferon beta chain genes. IRF4 expression is tightly regulated in resting primary T cells and plays an essential role in the homeostasis and function of mature lymphocytes. IRF4 is induced by Toll-like receptor (TLR) activation and acts as a negative regulator of TLR signaling. |
IRF4 Antibody |
6307-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: IRF4 Antibody: Interferons (IFNs) are involved in a multitude of immune interactions during viral infections and play a major role in both the induction and regulation of innate and adaptive antiviral mechanisms. During infection, host-virus interactions signal downstream molecules such as transcription factors such as IFN regulatory factor-3 (IRF3) which can act to stimulate transcription of IFN-alpha/beta genes. Another member, IRF7 has been shown to play a role in the transcriptional activation of virus-inducible cellular genes, including interferon beta chain genes. IRF4 expression is tightly regulated in resting primary T cells and plays an essential role in the homeostasis and function of mature lymphocytes. IRF4 is induced by Toll-like receptor (TLR) activation and acts as a negative regulator of TLR signaling. |
IRF4 antibody |
70R-18008 |
Fitzgerald |
50 ul |
EUR 522 |
Description: Rabbit polyclonal IRF4 antibody |
IRF4 antibody |
70R-31899 |
Fitzgerald |
100 ug |
EUR 392.4 |
Description: Rabbit polyclonal IRF4 antibody |
IRF4 antibody |
70R-51567 |
Fitzgerald |
100 ul |
EUR 292.8 |
Description: Purified Polyclonal IRF4 antibody |
IRF4 Antibody |
33893-100ul |
SAB |
100ul |
EUR 302.4 |
IRF4 Antibody |
33893-50ul |
SAB |
50ul |
EUR 224.4 |
IRF4 Antibody |
1-CSB-PA220104 |
Cusabio |
|
|
|
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:1000-1:2000, WB:1:200-1:1000 |
IRF4 Antibody |
CSB-PA250376- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
IRF4 Antibody |
CSB-PA250376-100ul |
Cusabio |
100ul |
EUR 379.2 |
|
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
IRF4 Antibody |
1-CSB-PA668482 |
Cusabio |
|
|
|
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:1000-1:2000, WB:1:200-1:1000 |
IRF4 Antibody |
1-CSB-PA003064 |
Cusabio |
|
|
|
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000 |
IRF4 Antibody |
1-CSB-PA011819ESR2HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
IRF4 Antibody |
1-CSB-PA011819GA01HU |
Cusabio |
|
|
|
Description: A polyclonal antibody against IRF4. Recognizes IRF4 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC |
IRF4 Antibody |
F42346-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
Description: The protein encoded by this gene belongs to the IRF (interferon regulatory factor) family of transcription factors, characterized by an unique tryptophan pentad repeat DNA-binding domain. The IRFs are important in the regulation of interferons in response to infection by virus, and in the regulation of interferon-inducible genes. This family member is lymphocyte specific and negatively regulates Toll-like-receptor (TLR) signaling that is central to the activation of innate and adaptive immune systems. A chromosomal translocation involving this gene and the IgH locus, t(6;14)(p25;q32), may be a cause of multiple myeloma. Alternatively spliced transcript variants have been found for this gene. |
IRF4 Antibody |
F42346-0.4ML |
NSJ Bioreagents |
0.4 ml |
EUR 322.15 |
Description: The protein encoded by this gene belongs to the IRF (interferon regulatory factor) family of transcription factors, characterized by an unique tryptophan pentad repeat DNA-binding domain. The IRFs are important in the regulation of interferons in response to infection by virus, and in the regulation of interferon-inducible genes. This family member is lymphocyte specific and negatively regulates Toll-like-receptor (TLR) signaling that is central to the activation of innate and adaptive immune systems. A chromosomal translocation involving this gene and the IgH locus, t(6;14)(p25;q32), may be a cause of multiple myeloma. Alternatively spliced transcript variants have been found for this gene. |
IRF4 Antibody |
R34209-100UG |
NSJ Bioreagents |
100 ug |
EUR 339.15 |
Description: Additional name(s) for this target protein: Interferon regulatory factor 4 |
IRF4 Rabbit pAb |
A1052-50ul |
Abclonal |
50 ul |
EUR 267.6 |
IRF4 Rabbit pAb |
A1052-100ul |
Abclonal |
100 ul |
EUR 369.6 |
IRF4 Rabbit pAb |
A1052-200ul |
Abclonal |
200 ul |
EUR 550.8 |
IRF4 Rabbit pAb |
A1052-20ul |
Abclonal |
20 ul |
EUR 219.6 |
IRF4 Rabbit pAb |
A0524-100ul |
Abclonal |
100 ul |
EUR 369.6 |
IRF4 Rabbit pAb |
A0524-200ul |
Abclonal |
200 ul |
EUR 550.8 |
IRF4 Rabbit pAb |
A0524-20ul |
Abclonal |
20 ul |
EUR 219.6 |
IRF4 Rabbit pAb |
A0524-50ul |
Abclonal |
50 ul |
EUR 267.6 |
anti- IRF4 antibody |
FNab04390 |
FN Test |
100µg |
EUR 658.5 |
|
Description: Antibody raised against IRF4 |
IRF4 Antibody (MUM1) |
R31635 |
NSJ Bioreagents |
100 ug |
EUR 356.15 |
Description: Interferon regulatory factor 4, also known as MUM1, is a protein that in humans is encoded by the IRF4 gene. It is located on 6p25.3. IRF4 is a transcription factor, and it is essential for the development of T helper-2 (Th2) cells, IL17 -producing Th17 cells, and IL9 -producing Th9 cells. In melanocytic cells, the gene may be regulated by MITF. IRF4 is a transcription factor that has been implicated in acute leukemia. This gene is strongly associated with pigmentation, sensitivity of skin to sun exposure, freckles, blue eyes, and brown hair color. Additionally, IRF4 inhibition is toxic to myeloma cell lines, regardless of transforming oncogenic mechanism. |
IRF4 cloning plasmid |
CSB-CL011819HU-10ug |
Cusabio |
10ug |
EUR 279.6 |
|
Description: A cloning plasmid for the IRF4 gene. |
Polyclonal IRF4 Antibody |
APR06706G |
Leading Biology |
0.1 mg |
EUR 790.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human IRF4 . This antibody is tested and proven to work in the following applications: |
IRF4 Conjugated Antibody |
C37663 |
SAB |
100ul |
EUR 476.4 |
IRF4 Conjugated Antibody |
C38169 |
SAB |
100ul |
EUR 476.4 |
TKD Peptide (Hsp70 Peptide) (Hsp70 Peptide) |
SIH-118A |
Stressmarq |
1 mg |
EUR 374.4 |
|
Description: The substance TKD Peptide (Hsp70 Peptide) is a hsp70 peptide. It is synthetically produced and has a purity of >98%. The pure substance is solid which is In aqueous solution. |
TKD Peptide (Hsp70 Peptide): FITC (Hsp70 Peptide) |
SIH-119A |
Stressmarq |
1 mg |
EUR 430.8 |
|
Description: The substance TKD Peptide (Hsp70 Peptide): FITC is a hsp70 peptide. It is synthetically produced and has a purity of >98%. The pure substance is solid which is In aqueous solution. |
Human IRF4 shRNA Plasmid |
20-abx952455 |
Abbexa |
|
|
|
Mouse IRF4 shRNA Plasmid |
20-abx971073 |
Abbexa |
|
|
|
Anti-MUM1/IRF4 Antibody |
PB9222 |
BosterBio |
100ug/vial |
EUR 400.8 |
TKD Peptide (Hsp70 Peptide) |
abx076809-1mg |
Abbexa |
1 mg |
EUR 594 |
|
IRF4 Recombinant Protein (Rat) |
RP206234 |
ABM |
100 ug |
Ask for price |
IRF4 Recombinant Protein (Human) |
RP016315 |
ABM |
100 ug |
Ask for price |
IRF4 Recombinant Protein (Mouse) |
RP144200 |
ABM |
100 ug |
Ask for price |
Rat Peptide YY (PYY) Peptide |
20-abx068453 |
Abbexa |
-
EUR 744.00
-
EUR 326.40
-
EUR 2230.80
-
EUR 878.40
-
EUR 543.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Connecting Peptide (C-Peptide) Peptide |
abx670072-05mg |
Abbexa |
0.5 mg |
EUR 678 |
|
Human Peptide YY (PYY) Peptide |
20-abx068451 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2013.60
-
EUR 811.20
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Peptide YY (PYY) Peptide |
20-abx068452 |
Abbexa |
-
EUR 710.40
-
EUR 309.60
-
EUR 2131.20
-
EUR 844.80
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
TKD Peptide (Hsp70 Peptide) (FITC) |
abx076810-1mg |
Abbexa |
1 mg |
EUR 678 |
|
Rat Connecting Peptide (C-Peptide) Peptide (OVA) |
20-abx651058 |
Abbexa |
-
EUR 510.00
-
EUR 276.00
-
EUR 1378.80
-
EUR 594.00
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dog Peptide YY (PYY) Peptide (OVA) |
20-abx651198 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Pig Peptide YY (PYY) Peptide (OVA) |
20-abx651200 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Peptide YY (PYY) Peptide (OVA) |
20-abx651201 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Irf4 ORF Vector (Rat) (pORF) |
ORF068746 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Mouse Peptide YY (PYY) Peptide (OVA) |
20-abx651199 |
Abbexa |
-
EUR 427.20
-
EUR 260.40
-
EUR 1178.40
-
EUR 526.80
-
EUR 343.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Peptide YY (PYY) Peptide (OVA) |
20-abx651848 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
IRF4 ORF Vector (Human) (pORF) |
ORF005439 |
ABM |
1.0 ug DNA |
EUR 114 |
Irf4 ORF Vector (Mouse) (pORF) |
ORF048068 |
ABM |
1.0 ug DNA |
EUR 607.2 |
IRF4 ELISA Kit (Rat) (OKCD04470) |
OKCD04470 |
Aviva Systems Biology |
96 Wells |
EUR 1028.4 |
Description: Description of target: ;Species reactivity: Rat;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.133 ng/mL |
Rat Galanin Like Peptide (GALP) Peptide |
20-abx650475 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2364.00
-
EUR 927.60
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Peptide 810 |
H-2586.0001 |
Bachem |
1.0mg |
EUR 529.2 |
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1] |
Peptide 810 |
H-2586.0005 |
Bachem |
5.0mg |
EUR 2010 |
Description: Sum Formula: C59H91N13O17S; CAS# [156371-22-1] |
Recombinant Human IRF4 / MUM-1 |
7-05413 |
CHI Scientific |
2µg |
Ask for price |
Recombinant Human IRF4 / MUM-1 |
7-05414 |
CHI Scientific |
5µg |
Ask for price |
Recombinant Human IRF4 / MUM-1 |
7-05415 |
CHI Scientific |
10µg |
Ask for price |
IRF4 ELISA Kit (Mouse) (OKCA00901) |
OKCA00901 |
Aviva Systems Biology |
96 Wells |
EUR 999.6 |
Description: Description of target: Transcriptional activator. Binds to the interferon-stimulated response element (ISRE) of the MHC class I promoter. Binds the immunoglobulin lambda light chain enhancer, together with PU.1. Probably plays a role in ISRE-targeted signal transduction mechanisms specific to lymphoid cells. Involved in CD8+ dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, leading to recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF4 and activation of genes.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 3.9 pg/mL |
Formyl Peptide Receptor-like 2 Peptide |
43-293P |
ProSci |
0.1 mg |
EUR 405.6 |
Dog Brain Natriuretic Peptide (BNP) Peptide |
20-abx065598 |
Abbexa |
-
EUR 1062.00
-
EUR 393.60
-
EUR 3400.80
-
EUR 1262.40
-
EUR 727.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Pig Brain Natriuretic Peptide (BNP) Peptide |
20-abx065601 |
Abbexa |
-
EUR 994.80
-
EUR 376.80
-
EUR 3199.20
-
EUR 1195.20
-
EUR 693.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Brain Natriuretic Peptide (BNP) Peptide |
20-abx652109 |
Abbexa |
-
EUR 910.80
-
EUR 360.00
-
EUR 2865.60
-
EUR 1095.60
-
EUR 644.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Polyclonal IRF4 Antibody (C-Term) |
APG00796G |
Leading Biology |
0.1mg |
EUR 580.8 |
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human IRF4 (C-Term). This antibody is tested and proven to work in the following applications: |
IRF4(Phospho-Tyr122/125) antibody |
12846-100ul |
SAB |
100ul |
EUR 302.4 |
IRF4(Phospho-Tyr122/125) antibody |
12846-50ul |
SAB |
50ul |
EUR 224.4 |
Canine C Peptide(C Peptide) ELISA Kit |
ECA0028 |
FN Test |
96T |
EUR 681.12 |
|
Description: Method of detection: Coated with Antigen, Competitive ELISA;Reacts with: Canine;Sensitivity: 0.469 ng/ml |
Rat Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065483 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065484 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2331.60
-
EUR 910.80
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065486 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2331.60
-
EUR 910.80
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Cow Atrial Natriuretic Peptide (ANP) Peptide |
20-abx166288 |
Abbexa |
-
EUR 878.40
-
EUR 343.20
-
EUR 2766.00
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide |
20-abx065599 |
Abbexa |
-
EUR 878.40
-
EUR 343.20
-
EUR 2766.00
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Brain Natriuretic Peptide (BNP) Peptide |
20-abx065600 |
Abbexa |
-
EUR 895.20
-
EUR 360.00
-
EUR 2798.40
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Brain Natriuretic Peptide (BNP) Peptide |
20-abx065602 |
Abbexa |
-
EUR 895.20
-
EUR 360.00
-
EUR 2798.40
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain natriuretic peptide (BNP) Peptide |
abx670010-01mg |
Abbexa |
0.1 mg |
EUR 360 |
|
Human Osteogenic Growth Peptide (OGP) Peptide |
20-abx652290 |
Abbexa |
-
EUR 661.20
-
EUR 292.80
-
EUR 1914.00
-
EUR 777.60
-
EUR 493.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Atrial Natriuretic Peptide (ANP) Peptide |
20-abx065482 |
Abbexa |
-
EUR 811.20
-
EUR 343.20
-
EUR 2498.40
-
EUR 961.20
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Atrial Natriuretic Peptide (ANP) Peptide |
20-abx652084 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
IRF4 Colorimetric Cell-Based ELISA |
EKC1819 |
BosterBio |
100ul |
EUR 686.4 |
Rat Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx069656 |
Abbexa |
-
EUR 844.80
-
EUR 343.20
-
EUR 2598.00
-
EUR 994.80
-
EUR 594.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Vasoactive Intestinal Peptide (VIP) Peptide (OVA) |
20-abx651057 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1296.00
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Cow Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx166274 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2331.60
-
EUR 910.80
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Polyclonal IRF4 Antibody (C-Terminus) |
APR02881G |
Leading Biology |
0.05mg |
EUR 580.8 |
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human IRF4 (C-Terminus). This antibody is tested and proven to work in the following applications: |
Rat C- Peptide, connecting peptide ELISA Kit |
CELI-66099r |
Lifescience Market |
96 Tests |
EUR 1063.2 |
Glucagon-Like Peptide 1 (GLP1) Peptide (OVA) |
20-abx651107 |
Abbexa |
-
EUR 510.00
-
EUR 276.00
-
EUR 1378.80
-
EUR 594.00
-
EUR 376.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx069654 |
Abbexa |
-
EUR 794.40
-
EUR 326.40
-
EUR 2448.00
-
EUR 944.40
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx069655 |
Abbexa |
-
EUR 828.00
-
EUR 343.20
-
EUR 2548.80
-
EUR 978.00
-
EUR 594.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Vasoactive Intestinal Peptide (VIP) Peptide |
20-abx652275 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2013.60
-
EUR 811.20
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human C- Peptide, connecting peptide ELISA Kit |
CELI-66099h |
Lifescience Market |
96 Tests |
EUR 988.8 |
Mouse C- Peptide, connecting peptide ELISA Kit |
CELI-66099m |
Lifescience Market |
96 Tests |
EUR 1038 |
Rat C-Type Natriuretic Peptide (NPPC) Peptide |
20-abx066176 |
Abbexa |
-
EUR 811.20
-
EUR 343.20
-
EUR 2498.40
-
EUR 961.20
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Gastrin Releasing Peptide (GRP) Peptide (OVA) |
20-abx651230 |
Abbexa |
-
EUR 376.80
-
EUR 243.60
-
EUR 927.60
-
EUR 410.40
-
EUR 309.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Glucagon-Like Peptide 2 (GLP2) Peptide |
abx670345-1mg |
Abbexa |
1 mg |
EUR 427.2 |
|
PEPT2 Peptide |
42-289P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (CT) PEPT2 Peptide |
Bovine C- Peptide, connecting peptide ELISA Kit |
CELI-66099b |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Canine C- Peptide, connecting peptide ELISA Kit |
CELI-66099d |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Rabbit C- Peptide, connecting peptide ELISA Kit |
CELI-66099Rb |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Cow Atrial Natriuretic Peptide (ANP) Peptide (OVA) |
20-abx651048 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1296.00
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Dog Atrial Natriuretic Peptide (ANP) Peptide (OVA) |
20-abx651049 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1296.00
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Pig Atrial Natriuretic Peptide (ANP) Peptide (OVA) |
20-abx651051 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1296.00
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
HA Peptide |
20-abx266124 |
Abbexa |
-
EUR 493.20
-
EUR 794.40
-
EUR 376.80
|
|
|
HP Peptide |
42-911P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) HP beta chain peptide |
HP Peptide |
42-912P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) HP alpha chain peptide |
C3 Peptide |
43-098P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: C3 Peptide |
C3 Peptide |
43-099P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: C3 Peptide |
C9 Peptide |
43-483P |
ProSci |
0.1 mg |
EUR 405.6 |
KL Peptide |
42-061P |
ProSci |
0.1 mg |
EUR 405.6 |
Description: (IN) Klotho / KL Peptide |
Peptide e |
H-3236.0500 |
Bachem |
0.5mg |
EUR 327.6 |
Description: Sum Formula: C83H155N39O21S; CAS# [120253-69-2] |
Peptide e |
H-3236.1000 |
Bachem |
1.0mg |
EUR 559.2 |
Description: Sum Formula: C83H155N39O21S; CAS# [120253-69-2] |
Peptide 46 |
H-4054.0500 |
Bachem |
0.5mg |
EUR 618 |
Description: Sum Formula: C100H174N40O31; CAS# [192122-40-0] |
Peptide 46 |
H-4054.1000 |
Bachem |
1.0mg |
EUR 1082.4 |
Description: Sum Formula: C100H174N40O31; CAS# [192122-40-0] |
Peptide 6A |
H-6905.0005 |
Bachem |
5.0mg |
EUR 356.4 |
Description: Sum Formula: C23H43N9O6; CAS# [73549-32-3] |
Peptide 6A |
H-6905.0025 |
Bachem |
25.0mg |
EUR 1311.6 |
Description: Sum Formula: C23H43N9O6; CAS# [73549-32-3] |
Peptide 74 |
H-8545.0500 |
Bachem |
0.5mg |
EUR 254.4 |
Description: Sum Formula: C62H107N23O20S2; CAS# [132116-39-3] |
Peptide 74 |
H-8545.1000 |
Bachem |
1.0mg |
EUR 400.8 |
Description: Sum Formula: C62H107N23O20S2; CAS# [132116-39-3] |
Rat Cathelicidin Antimicrobial Peptide (CAMP) Peptide |
20-abx065801 |
Abbexa |
-
EUR 895.20
-
EUR 343.20
-
EUR 2781.60
-
EUR 1062.00
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Chicken C- Peptide, connecting peptide ELISA Kit |
CELI-66099c |
Lifescience Market |
96 Tests |
EUR 1113.6 |
General C- Peptide, connecting peptide ELISA Kit |
CELI-66099Ge |
Lifescience Market |
96 Tests |
EUR 1063.2 |
Porcine C- Peptide, connecting peptide ELISA Kit |
CELI-66099p |
Lifescience Market |
96 Tests |
EUR 1113.6 |
Human C-Type Natriuretic Peptide (NPPC) Peptide |
20-abx066173 |
Abbexa |
-
EUR 744.00
-
EUR 326.40
-
EUR 2230.80
-
EUR 878.40
-
EUR 543.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse C-Type Natriuretic Peptide (NPPC) Peptide |
20-abx066174 |
Abbexa |
-
EUR 811.20
-
EUR 343.20
-
EUR 2498.40
-
EUR 961.20
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse C-Type Natriuretic Peptide (NPPC) Peptide |
20-abx066178 |
Abbexa |
-
EUR 811.20
-
EUR 343.20
-
EUR 2498.40
-
EUR 961.20
-
EUR 577.20
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Antigen Peptide Transporter 2 (TAP2) Peptide |
20-abx650297 |
Abbexa |
-
EUR 727.20
-
EUR 309.60
-
EUR 2197.20
-
EUR 861.60
-
EUR 526.80
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (BSA) |
20-abx651076 |
Abbexa |
-
EUR 393.60
-
EUR 243.60
-
EUR 1011.60
-
EUR 477.60
-
EUR 326.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (OVA) |
20-abx651077 |
Abbexa |
-
EUR 693.60
-
EUR 309.60
-
EUR 2064.00
-
EUR 828.00
-
EUR 510.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (OVA) |
20-abx651078 |
Abbexa |
-
EUR 309.60
-
EUR 226.80
-
EUR 678.00
-
EUR 343.20
-
EUR 276.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (OVA) |
20-abx651079 |
Abbexa |
-
EUR 326.40
-
EUR 226.80
-
EUR 727.20
-
EUR 360.00
-
EUR 276.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Brain Natriuretic Peptide (BNP) Peptide (OVA) |
20-abx651080 |
Abbexa |
-
EUR 309.60
-
EUR 226.80
-
EUR 678.00
-
EUR 343.20
-
EUR 276.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Gastrin Releasing Peptide (GRP) Peptide (BSA) |
20-abx651228 |
Abbexa |
-
EUR 493.20
-
EUR 260.40
-
EUR 1262.40
-
EUR 560.40
-
EUR 360.00
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Mouse Gastrin Releasing Peptide (GRP) Peptide (OVA) |
20-abx651229 |
Abbexa |
-
EUR 376.80
-
EUR 243.60
-
EUR 927.60
-
EUR 410.40
-
EUR 309.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide |
20-abx652283 |
Abbexa |
-
EUR 376.80
-
EUR 243.60
-
EUR 927.60
-
EUR 410.40
-
EUR 309.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Human Amyloid Beta Peptide 1-40 (Ab1-40) Peptide |
abx670346-1mg |
Abbexa |
1 mg |
EUR 627.6 |
|
Rat Natriuretic Peptide Receptor 3 (NPR3) Peptide |
20-abx168540 |
Abbexa |
-
EUR 878.40
-
EUR 343.20
-
EUR 2749.20
-
EUR 1045.20
-
EUR 627.60
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
Rat Calcitonin Gene Related Peptide (CGRP) Peptide |
20-abx065659 |
Abbexa |
-
EUR 777.60
-
EUR 326.40
-
EUR 2331.60
-
EUR 910.80
-
EUR 560.40
|
- 100 ug
- 10 ug
- 1 mg
- 200 ug
- 50 ug
|
|
The equivalent calculation of dissolved methane is also presented as a benchmark for comparison. This study calls for reassessing troops that stabilize the conformation of proteins folded in aqueous solution and additives of hydrophobic / hydrophilic contributions.